While several factors currently limit its feasibility as a direct therapeutic target, the isoform-specific functions of GFPT1 and GFPT2 present an opportunity to develop cancer subtype-specific biomarkers and may inform the design of more selective therapeutic strategies. This evidence concerns the gene GFPT2 and cancer.